Homology Medicines, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 34.3 million compared to USD 33.58 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.59 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | -11.56% | -14.36% | +137.57% |
05-21 | Leerink Partners Starts Q32 Bio With Outperform Rating | MT |
05-09 | Q32 Bio Inc. Provides Corporate Update | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+137.57% | 310M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Homology Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022